From the Department of Pharmacology and Chemical Biology, University of Pittsburgh, Pittsburgh, Pennsylvania 15261.
Women's Cancer Research Center, University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh, Pennsylvania 15213.
J Biol Chem. 2019 Jan 11;294(2):397-404. doi: 10.1074/jbc.AC118.005899. Epub 2018 Nov 26.
Homologous recombination (HR)-directed DNA double-strand break (DSB) repair enables template-directed DNA repair to maintain genomic stability. RAD51 recombinase (RAD51) is a critical component of HR and facilitates DNA strand exchange in DSB repair. We report here that treating triple-negative breast cancer (TNBC) cells with the fatty acid nitroalkene 10-nitro-octadec-9-enoic acid (OA-NO) in combination with the antineoplastic DNA-damaging agents doxorubicin, cisplatin, olaparib, and γ-irradiation (IR) enhances the antiproliferative effects of these agents. OA-NO inhibited IR-induced RAD51 foci formation and enhanced H2A histone family member X (H2AX) phosphorylation in TNBC cells. Analyses of fluorescent DSB reporter activity with both static-flow cytometry and kinetic live-cell studies enabling temporal resolution of recombination revealed that OA-NO inhibits HR and not nonhomologous end joining (NHEJ). OA-NO alkylated Cys-319 in RAD51, and this alkylation depended on the Michael acceptor properties of OA-NO because nonnitrated and saturated nonelectrophilic analogs of OA-NO, octadecanoic acid and 10-nitro-octadecanoic acid, did not react with Cys-319. Of note, OA-NO alkylation of RAD51 inhibited its binding to ssDNA. RAD51 Cys-319 resides within the SH3-binding site of ABL proto-oncogene 1, nonreceptor tyrosine kinase (ABL1), so we investigated the effect of OA-NO-mediated Cys-319 alkylation on ABL1 binding and found that OA-NO inhibits RAD51-ABL1 complex formation both and in cell-based immunoprecipitation assays. The inhibition of the RAD51-ABL1 complex also suppressed downstream RAD51 Tyr-315 phosphorylation. In conclusion, RAD51 Cys-319 is a functionally significant site for adduction of soft electrophiles such as OA-NO and suggests further investigation of lipid electrophile-based combinational therapies for TNBC.
同源重组 (HR)-定向 DNA 双链断裂 (DSB) 修复使模板指导的 DNA 修复能够维持基因组稳定性。RAD51 重组酶 (RAD51) 是 HR 的关键组成部分,促进 DSB 修复中的 DNA 链交换。我们在这里报告,用脂肪酸硝烯 10-硝基-十八-9-烯酸 (OA-NO) 联合抗肿瘤 DNA 损伤药物阿霉素、顺铂、奥拉帕利和 γ 辐射 (IR) 处理三阴性乳腺癌 (TNBC) 细胞,增强了这些药物的抗增殖作用。OA-NO 抑制了 IR 诱导的 RAD51 焦点形成,并增强了 TNBC 细胞中的组蛋白家族成员 X (H2AX) 的磷酸化。使用静态流式细胞术和动力学活细胞研究对荧光 DSB 报告活性的分析,使重组的时间分辨率得以实现,结果表明 OA-NO 抑制 HR 而不是非同源末端连接 (NHEJ)。OA-NO 使 RAD51 的半胱氨酸 319 烷基化,并且这种烷基化依赖于 OA-NO 的迈克尔受体特性,因为非硝化和饱和的非电中性 OA-NO 类似物,十八烷酸和 10-硝基-十八烷酸,不与半胱氨酸 319 反应。值得注意的是,OA-NO 对 RAD51 的烷基化抑制了其与 ssDNA 的结合。RAD51 的半胱氨酸 319 位于 ABL 原癌基因 1、非受体酪氨酸激酶 (ABL1) 的 SH3 结合位点内,因此我们研究了 OA-NO 介导的半胱氨酸 319 烷基化对 ABL1 结合的影响,并发现 OA-NO 抑制 RAD51-ABL1 复合物的形成,并且在细胞内免疫沉淀测定中也是如此。RAD51-ABL1 复合物的抑制也抑制了 RAD51 酪氨酸 315 的磷酸化。总之,RAD51 的半胱氨酸 319 是亲电软试剂如 OA-NO 加成的功能重要位点,并提示进一步研究基于脂质亲电试剂的组合疗法用于 TNBC。